Sanofi (Euronext: SAN) has signed a strategic agreement with health authorities in Abu Dhabi to accelerate vaccine development and manufacturing in the United Arab Emirates. The deal was announced at the BIO International Convention in Boston and signals a bold move to position Abu Dhabi as a rising player in global health innovation.
The memorandum of understanding aims to streamline clinical development timelines, improve regulatory alignment and build manufacturing capacity in the region.
The project will include the use of real-time data and artificial intelligence, leveraging the research infrastructure of the region and Sanofi’s scientific expertise.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze